Non-alcoholic fatty liver disease and cardiovascular pathology: a vicious circle of common pathogenesis

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver diseases. According to modern concepts, a unique feature of this pathology is that patients with NAFLD have a significantly increased risk of developing not only liver diseases, but also extrahepatic pathologies, mainly cardiovascular diseases (CVD). Various studies have clearly demonstrated the predictive role of NAFLD in the development of arterial hypertension, coronary heart disease, myocardial infarction, cardiac arrhythmias, and cardiovascular mortality. The commonality of pathogenetic mechanisms underlying NAFLD and CVD is discussed, primarily such as: dyslipidemia, hypertriglyceridemia, insulin resistance, lipotoxicity and chronic sterile inflammation. This review article analyzes the relationship between NAFLD and CVDs, describes the pathophysiological mechanisms of the bidirectional influence of these pathologies.

1. WHO. Obesity and overweight [Internet]. World Health Organization. 2024. Available at: https://www. who.int/news-room/fact-sheets/detail/obesity-and-overweight

2. Non-alcoholic fatty liver disease in adults. Clinical guidelines of the Ministry of Health of Russia. 2024. (In Russ.) Available at https://cr.minzdrav.gov.ru/preview-cr/748_2

3. Muzurović E., Mikhailidis D.P., Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021 Jun;119:154770. https://doi.org/10.1016/j.metabol.2021.154770

4. Evstifeeva S.E., Shalnova S.A., Kutsenko V.A., et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356. (In Russ.). https://doi.org/10.15829/1728-8800-2022-3356

5. Kotovskaya YuV. Non-alcoholic fatty liver disease and cardiovascular risks: A review. Consilium Medicum. 2023;25(4):253-258. (In Russ.). https://doi.org/10.26442/20751753.2023.4.202275

6. Muzica C.M., Sfarti C., Trifan A., et al. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Filipović B, editor. Canadian Journal of Gastroenterology and Hepatology. 2020 Dec 28;2020: 6638306. https://doi.org/10.1155/2020/6638306

7. Kim D., Adejumo A.C., Yoo E.R., et al. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. Gastroenterology 2019;157:1055-1066. https://doi.org/10.1053/j.gastro.2019.06.026

8. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in nonalcoholic fatty liver disease. Journal of Hepatology. 2008 Oct;49(4):608-12. https://doi.org/10.1016/j.jhep.2008.06.018

9. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2021 Nov;6(11):903-913. https://doi.org/10.1016/s2468-1253(21)00308-3

10. Pais R, Giral P, Khan JF, et al. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol 2016; 65: 95-102. https://doi.org/10.1016/j.jhep.2016.02.023

11. Pipitone R.M., Ciccioli C., Infantino G., et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023 Jan 28;14:20420188221145549. https://doi.org/10.1177/20420188221145549

12. Da S. George J., Qiao L. From MAFLD to hepatocellular carcinoma and everything in between. Chin Med J (Engl). 2022 Feb 21;135(5):547-556. https://doi.org/10.1097/cm9.0000000000002089

13. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Digestive Diseases and Sciences. 2013 Jun 18;58(10):3017-23. https://doi.org/10.1007/s10620-013-2743-5

14. Podzolkov V.I. Arterial hypertension. – M.: OOO "Izdatelstvo" Medical Information Agency", 2016. – 424 p. (In Russ.)

15. Nasiri-Ansari N., Androutsakos T., Flessa C.M., et al. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells. 2022 Aug 12;11(16):2511. https://doi.org/10.3390/cells11162511

16. Poisson J., Lemoinne S., Boulanger C., et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J. Hepatol. 2017, 66, 212-227. https://doi.org/10.1016/j.jhep.2016.07.009

17. El-Shammaa M.A., El-Shafey S.M., El H., et al. Sea bream liver: histological and ultrastructure studies (i) hepatocytes. Kafrelsheikh Veterinary Medical Journal. 2008 Apr 12;6(1):1-31.

18. Hazrati A., Malekpour K., Soudi S., et al. Mesenchymal Stromal/Stem Cells and Their Extracellular Vesicles Application in Acute and Chronic Inflammatory Liver Diseases: Emphasizing on the Anti-Fibrotic and Immunomodula tory Mechanisms. Frontiers in immunology. 2022 Apr 7:13:865888. https://doi.org/10.3389/fimmu.2022.865888

19. Li P., He K., Li J., Liu Z, Gong J. The role of Kupffer cells in hepatic diseases. Mol Immunol. 2017 May;85:222- 229. https://doi.org/10.1016/j.molimm.2017.02.018

20. Jain H., Pervez N., Dey D., et al. Non-alcoholic fatty liver disease is associated with coronary flow reserve impairment: A pilot meta-analysis. Medicine. 2024 Sep 6;103(36):e39499-9. https://doi.org/10.1097/md.0000000000039499

21. Kasper P., Martin A., Lang S., et al. NAFLD and cardiovascular diseases: a clinical review. Clinical Research in Cardiology: Official Journal of the German Cardiac Society [Internet]. 2020 Jul 21;110(7). Available from: https://pubmed.ncbi.nlm.nih.gov/32696080/

22. Liu K., Tang S., Liu C., et al. Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk. Frontiers in Immunology. 2024 Feb 28;15:1337241. https://doi.org/10.3389/fimmu.2024.1337241

23. Chen Z., Tian R., She Z., et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radical Biology and Medicine [Internet]. 2020 May 20;152:116-141. https://doi.org/10.1016/j.freeradbiomed.2020.02.025

24. Kravchenko S.D., Kozlova N.M., Tirikova O.V. Oxidative stress evaluation methods as potential biomarkers in NAFLD. International Research Journal. 2022;8(122):1-14. (In Russ.). https://doi.org/10.23670/IRJ.2022.122.86

25. Lechner K., McKenzie A.L., Kränkel N., et al. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. Metabolic Syndrome and Related Disorders. 2020 May 1;18(4):176-85. https://doi.org/10.1089/met.2019.0115

26. Kim D., Choi S.Y., Park E.H., et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012 Jul 2;56(2):605-13. https://doi.org/10.1002/hep.25593

27. Song J., Ma R., Yin L. Associations between estimated glucose disposal rate and arterial stiffness and mortality among US adults with non-alcoholic fatty liver disease. Frontiers in endocrinology. 2024 May 8:15:1398265. https://doi.org/10.3389/fendo.2024.1398265

28. Jaruvongvanich V., Chenbhanich J., Sanguankeo A., et al. Increased arterial stiffness in nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology. 2017 Sep;29(9):e28-35. https://doi.org/10.1097/meg.0000000000000909

29. Hirata A., Harada S., Iida M., et al. Association of Nonalcoholic Fatty Liver Disease with Arterial Stiffness and its Metabolomic Profiling in Japanese Community-Dwellers. Journal of Atherosclerosis and Thrombosis. 2024 Feb 1;31(7):1031-1047. https://doi.org/10.5551/jat.64616

30. Miyoshi T., Ito H. Arterial stiffness in health and disease: The role of cardio–ankle vascular index. Journal of Cardiology [Internet]. 2021 Dec 1;78(6):493-501. https://doi.org/10.1016/j.jjcc.2021.07.011

31. Dubsky M., Veleba J., Sojakova D., et al. Endothelial Dysfunction in Diabetes Mellitus: New Insights. International Journal of Molecular Sciences [Internet]. 2023 Jan 1;24(13):10705. https://doi.org/10.3390/ ijms241310705

32. Cao L., An Y., Liu H., et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. BMC medicine. 2024 Mar 6;22(1):101. https://doi.org/10.1186/s12916-024-03315-0

33. En Li Cho E., Ang C.Z., Quek J., et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut [Internet]. 2023;72(11):2138– 2148. https://doi.org/10.1136/gutjnl-2023-330110

34. Adams L.A., Anstee Q.M., Tilg H., et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut [Internet]. 2017 Jun 1 [cited 2021 May 31];66(6):1138–53. Available from: https://gut.bmj.com/content/66/6/1138

35. Boutari C., DeMarsilis A., Mantzoros C.S. Obesity and diabetes. Diabetes Research and Clinical Practice. 2023 Aug:202:110773. https://doi.org/10.1016/j.diabres.2023.110773

36. Mankieva E.G., Kukhareva E.I. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Russian Journal of Evidence-Based Gastroenterology. 2023;12(4):103-108. (In Russ.) https://doi.org/10.17116/dokgastro202312041103

37. Cusi K. Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology. 2012 Apr;142(4):711-725.e6. https://doi. org/10.1053/j.gastro.2012.02.003

38. Targher G., Corey K.E., Byrne C.D., et al. The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. Nature Reviews Gastroenterology & Hepatology [Internet]. 2021 Sep 1;18(9):599-612. https://doi.org/10.1038/s41575-021-00448-y

39. Mantovani A., Byrne C.D., Bonora E., Targher G. et al. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018 Jan 22;41(2):372-382. https://doi.org/10.2337/dc17-1902

40. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. Journal of Gastroenterology and Hepatology. 2016 Apr 28;31(5):936-44. https://doi.org/10.1111/jgh.13264

41. Au Yeung SL, Borges MC, Wong THT, et al. Evaluating the role of non-alcoholic fatty liver disease in cardiovascular diseases and type 2 diabetes: a Mendelian randomization study in Europeans and East Asians. Int J Epidemiol. 2023 Jun 6;52(3):921-931. https://doi.org/10.1093/ije/dyac212